Discover how Bergaptol, a promising compound, is making strides in the fight against glioma by targeting the STAT3/Bcl-2 pathway to halt cancer cell growth and trigger cell death.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Bergaptol inhibits glioma cell proliferation and induces apoptosis via STAT3/Bcl-2 pathway.
Huang et al., Anticancer Drugs 2024
<!– DOI: 10.1097/CAD.0000000000001603 //–>
https://doi.org/10.1097/CAD.0000000000001603
This study highlights the potential of bergaptol, a natural compound found in citrus products, as a therapeutic agent against glioblastoma (GBM), the most common and aggressive brain tumor. The research demonstrates that bergaptol can inhibit the proliferation and migration of GBM cell lines (U87 and A172) and induce apoptosis by targeting the STAT3/Bcl-2 signaling pathway, both in vitro and in vivo. Specifically, in a glioma mouse model, bergaptol treatment (40 mg/kg) significantly reduced tumor growth and extended survival times. This effect is attributed to bergaptol’s ability to inhibit the STAT3/Bcl-2 pathway, which is known to promote glioma progression by preventing apoptosis. The findings suggest that bergaptol could be a promising candidate for glioma therapy, offering a new avenue for treatment in a field where effective options are currently limited.